1	HLS/SLS 24-				
2	2024 Regular Session				
3	House/Senate Bill No				
4	By Representative/Senator				
5					
6	CONTROLLED DANGEROUS SUBSTANCES: Provides relative to schedules of the Uniform				
7	Controlled Dangerous Substances Law. Adds multiple substances to Schedule I, updates naming				
8	language in Schedule I, and adds Zuranolone to Schedule IV.				
9					
10	AN ACT				
11					
12	To amend and reenact R.S. 40:964, relative to naming language and the composition of various				
13	schedules of controlled substances.				
14	Be it enacted by the Legislature of Louisiana:				
15	Section 1. R.S. 40:964 is hereby amended and reenacted to read as follows:				
16	§964. Composition of schedules				
17	Schedules I, II, III, IV, and V shall, unless and until added pursuant to R.S. 40:962,				
18	consist of the following drugs or other substances, by whatever official name, common or				
19	usual name, chemical name, or brand name designated:				
20	SCHEDULE I				
21	A. Opiates. Unless specifically excepted or unless listed in another schedule, any of				
22	the following opiates, including their isomers, esters, ethers, salts, or salts of isomers,				
23	esters, and ethers, whenever the existence of such isomers, esters, ethers, or salts is				
24	possible within the specific chemical designation:				

25	* * *				
26	(101) 2,5-dimethoxyfentanyl (N-(1-(2,5-dimethoxyphenethyl)piperidine-4-yl)-				
27	N-phenylpropionamide)				
28	(102) alpha-methyl butyryl fentanyl (2-methyl-N-(1-phenethylpiperidin-4-yl)-				
29	N-phenylbutanamide)				
30	(103) para-methoxyfuranyl fentanyl (N-(4-methoxyphenyl)-N-(1-				
31	phenethylpiperidin-4-yl)furan-2-carboxamide)				
32	(104) para-methylcyclopropyl fentanyl (N-(4-methylphenyl)-N-(1-				
33	phenethylpiperidin-4-yl)cyclopropanecarboxamide)				
34	* * *				
35	C. Hallucinogenic substances. Unless specifically excepted or unless listed in				
36	another schedule, any material, compound, mixture, or preparation, which contains any				
37	quantity of the following hallucinogenic substances, or which contains any of their salts,				
38	isomers, or salts of isomers, whenever the existence of such salts, isomers, or salts of				
39	isomers is possible within the specific chemical designation, for purposes of this				
40	Subsection only, the term "isomer" includes the optical, position, and geometric isomers:				
41	* * *				
42	(69) 4-chloro-2,5-dimethoxyamphetamine				
43	(70) 4-iodo-2,5-dimethoxyamphetamine				
44	(71) 5-methoxy-alpha-methyltryptamine (5-MEO-AMT)				
45	(72) 5-methoxy-N,N-diethyltryptamine (5-MEO-DET)				
46	D. Depressants. Unless specifically excepted or unless listed in another schedule, any				
47	material, compound, mixture, or preparation which contains any quantity of the following				
48	substances having a depressant effect on the central nervous system, including its salts.				

isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

* * *

(8) Diclazepam

(9) Flubromazolam

(10) Bromazolam

* * *

F. Synthetic Cannabinoids. Unless specifically excepted, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of a synthetic cannabinoid found to be in any of the following individual compounds or chemical groups, or any of those individual compounds or groups which contain any synthetic cannabinoid salts, isomers, salts of isomers, or nitrogen-heterocyclic analogs, whenever the existence of such salts, isomers, salts of isomers, or nitrogen-heterocyclic analogs is possible within the specific compounds or chemical groups:

85 * * * *

(5) Butaldehydeamidoindoles: Any compound containing a N-(1-oxobutan-2yl)1H-indole-3-carboxamide structure, with or without substitution on the indole ring
by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl halide, arylalkylhalide
alkylarylhalide, cycloalkylmethyl, cycloalkylethyl, alkenyl, haloalkenyl, aliphatic
alcohol, hydroxyl, halide, morpholinoethyl, alkylmorpholinomethyl,
alkylpiperidinylmethyl or a tetrahydropyranylmethyl group, whether or not further
substituted on the butaldehyde group to any extent.

73	(6) Cumylindolecarboxamides: Any compound containing a N-(2-phenylpropane-					
74	2-yl)-1H-indole-3-carboxamide structure, with or without substitution on the indole					
75	ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl halide, arylalkylhalide					
76	alkylarylhalide, cycloalkylmethyl, cycloalkylethyl, alkenyl, haloalkenyl, aliphatic					
77	alcohol, hydroxyl, halide, morpholinoethyl, alkylmorpholinomethyl,					
78	alkylpiperidinylmethyl or a tetrahydropyranylmethyl group, whether or not further					
79	substituted on the phenyl group to any extent.					
80	* * *					
81	(26) Phenylpropionaldehydeamidoindoles: Any compound containing a N-(1-oxo-					
82	3-phenylpropan-2yl)-1H-indole-3-carboxamide structure, with or without					
83	substitution on the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkoxy, aryl, aryl					
84	halide, arylalkylhalide alkylarylhalide, cycloalkylmethyl, cycloalkylethyl,					
85	alkenyl, haloalkenyl, aliphatic alcohol, hydroxyl, halide, morpholinoethyl,					
86	alkylmorpholinomethyl, alkylpiperidinylmethyl or a tetrahydropyranylmethyl					
87	group, whether or not further substituted on the phenylpropionaldehyde group to					
88	any extent.					
89	* * *					
90	(30) 5-Pentyl-2-(2-phenylpropan-2-yl)pyrido[4,3-b]indole-1-one [Cumyl-					
91	Pegaclone; SGT-151]					
92	* * *					
93	SCHEDULE IV					
94	* * *					
95	B. Depressants. Unless specifically excepted or unless listed in another schedule, any					
96	material, compound, mixture, or preparation containing any quantity of the following					

97	substances, including its salts, isomers, and salts of isomers, whenever the existence of					
98	such salts, isomers, and salts of isomers is possible within the specific chemical					
99	designation:					
100		*	*	*		
101	(59) Zuranolone					
102		*	*	*		
103	Section 2. The Louisiana State Law Institute is hereby authorized and directed to					
104	renumber the substances to ensure that the substances are in alphabetical order.					
105	[END]					